Glatiramer acetate

K K Jain MD (

Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.

Originally released July 6, 1999; last updated November 2, 2020; expires November 2, 2023

Historical note and terminology

Glatiramer acetate, formerly called copolymer-1, is one of a series of polypeptide preparations developed to stimulate myelin basic protein, a natural component of the myelin sheath. Myelin basic protein suppresses experimental allergic encephalomyelitis (the animal model of multiple sclerosis); a better suppression effect was demonstrated by use of a synthetic basic copolymer (Teitelbaum et al 1974). This provided the rationale for the use of copolymer in multiple sclerosis. Glatiramer acetate was developed for commercial use, and results of the first clinical trial were published in 1987. The United States Food and Drug Administration approved it in 1996 for use in multiple sclerosis patients.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.

Find out how you can join MedLink Neurology